Biotechnology

RemeGen

RemeGen Approves 2.5B RMB Cash Management Plan, Invests 453M with HTSC in Fixed Income Products

Rongchang Biotech Purchases Multiple Wealth Management Products from SPDB Yantai Branch

RemeGen released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 656.21 M, actual EPS CNY 0.58

Rongchang Biotech Unveils Global First-in-Class PR-ADCs Platform at AACR and Reports Strong Performance

RemeGen FY2026 Q1 Earnings Release Scheduled for April 28 After-Market BJT

Rongchang Biotechnology and AbbVie Sign Exclusive Licensing Agreement for RC148 and Receive Upfront Payment

Rongchang Biopharmaceutical's Drug Receives Approval for Cancer Indication

Rongchang Biotech's Vensedotin New Indication Approved

CICC Raises Forecast for Rongchang Biotech's 2026 Net Profit and Target Price

Rongchang Biotech Announces Profitable 2025 Annual Report

Rongchang Biotechnology's RC288 Receives NMPA Approval for Clinical Trials

Rongchang Biotechnology Reports Profit of 710 Million Yuan for 2025 Year

Rongchang Biotech Announces 2025 Annual Report, Reversing Loss to Profit

Rongchang Biotechnology's Veseplimab Receives New Indication Approval

RemeGen to Release FY2025 Earnings on March 27 Pre-Market (BJT), Forecast Revenue CNY 2.982 B, EPS CNY 1.27

Rongchang Biotech to Hold Board Meeting to Approve Annual Results and Consider Dividend Payment

Rongchang Biotechnology Expected to Turn Profit in 2025

Nomura Predicts Robust Revenue and Profit Growth for RemeGen

Rongchang Bio achieved RMB 325,105.11 million in revenue in 2025, up 89.36%, with a net profit of RMB 70,852.33 million

RemeGen released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 1.531 B (forecast CNY 1.111 B), actual EPS CNY 2.2318

09995

688331

159849

516500

520690

159837

512290

159992

512010

159316

510660

159506

588250

520880

513120

159859

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

Tip Ranks

REMEGEN

China Merchants CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Penghua CSI HK Connect Health Care Composite ETF

China Southern Hang Seng Biotech ETF(QDII)

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

300765

China's pharmaceutical industry is rapidly evolving, with major companies like CSPC Pharmaceutical and RemeGen securing significant out-licensing agreements. The shift from low-cost manufacturing to high-value innovation is evident, particularly with the integration of AI in drug discovery. AI is compressing preclinical timelines and enhancing R&D capabilities. China now accounts for 30% of the global experimental drug pipeline and is a leader in antibody-drug conjugate projects. This growth has raised concerns among US lawmakers about China's potential dominance in the global pharmaceutical supply chain.

SCMP

CSPC Innovation

China’s drug makers are speeding up – will AI be their secret weapon?

002038

002923

588860

516820

688336

Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%

Wallstreetcn

SL PHARM

Rundu Pharma

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

NEPTUNUS

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Sunshine Guojian Pharmaceutical

HITECK

Cosunter

01877

In 2025, A-share biopharmaceutical companies are gradually moving from the "cash-burning R&D" stage to a new phase of "profit realization," benefiting from improved industry prosperity and policy support. As of March 29, over 70 biopharmaceutical companies have released their earnings. Among them, 61 companies achieved profitability, 29 companies saw year-on-year positive growth in net profit attributable to the parent company, and 7 companies doubled their profits. Furthermore, companies like RemeGen and InnoCare Pharma are expected to turn losses into profits, while companies such as MicuRx and Junshi Biosciences have reduced their losses

InnoCare Pharma

JUNSHI BIO

Junshi Biosciences

INNOCARE

MicuRx

Strong Growth in Innovative Drug Revenue, Biopharmaceutical Companies' Performance Shows High "Innovation" Content

RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

688513

Pharmaceutical stocks fluctuated and surged, with Getein Biotech hitting the daily limit, RemeGen rising nearly 7%, reaching a historical high. Sunshine Guojian Pharmaceutical, EASTON BIOPHARMACEUTICALS, YKYY, Junshi Biosciences, BeBetter Med, and InventisBio also followed suit

EASTON BIOPHARMACEUTICALS

BeBetter Med

InventisBio

Getein Biotech

YKYY

RemeGen (SEHK:9995) has reported a significant turnaround, moving from a net loss to a net profit for the full year 2025, with sales and earnings per share surpassing the previous year. The stock has seen a 10.92% increase in one day and a 15.82% rise year-to-date. However, its P/E ratio of 59.1x is considered high compared to the estimated fair P/E of 31.4x, indicating potential overvaluation. A DCF analysis suggests a fair value of HK$128.56, indicating a 33.6% discount at the current price of HK$85.3. Investors should weigh the high multiples against future cash flow potential and associated risks.

Simplywall

A Look At RemeGen’s Valuation After Its Strong Full Year Profit Turnaround

02618

00HSI

01530

The Hang Seng Index closed up 1.72%, and the Hang Seng Tech Index rose 3.15%. JD LOGISTICS rose over 20%, RemeGen rose over 10%, and 3SBIO rose over 8%. Yangtze Optical Fibre and Cable fell over 7%, and Sinopec Oilfield Service fell over 2%

JD LOGISTICS

Hang Seng Index

3SBIO

The Hang Seng Index closed up 1.72%, with the innovative drug sector leading the gains

RemeGen(688331.SH)

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

China’s drug makers are speeding up – will AI be their secret weapon?

Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%

Strong Growth in Innovative Drug Revenue, Biopharmaceutical Companies' Performance Shows High "Innovation" Content

RemeGen Wins Fourth NMPA Approval for Disitamab Vedotin in HER2-Low Breast Cancer

Pharmaceutical stocks fluctuated and surged, with Getein Biotech hitting the daily limit, RemeGen rising nearly 7%, reaching a historical high. Sunshine Guojian Pharmaceutical, EASTON BIOPHARMACEUTICALS, YKYY, Junshi Biosciences, BeBetter Med, and InventisBio also followed suit

A Look At RemeGen’s Valuation After Its Strong Full Year Profit Turnaround

The Hang Seng Index closed up 1.72%, with the innovative drug sector leading the gains